Nuformix receives new NXP001 development milestone payments in updated Oxilio agreement

Nuformix plc

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company is to receive new immediate and near-term undisclosed milestone payments as part of an update to its NXP001 exclusive licensing agreement with Oxilio Ltd.

Under the revised agreement with, Oxilio will acquire ownership of Nuformix’s NXP001 patent estate, with Nuformix receiving the additional milestone payments referred to above, whilst retaining further development milestones and royalties capped at £2 million per year.

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: “Oxilio has a clear plan as to how NXP001 fits into their overall product development plan and we continue to fully support Oxilio in that process.  The updated agreement has a dual benefit to Nuformix – we receive additional near-term cash payments, whilst discharging responsibility for future patent upkeep costs.  The net positive impact on our cash position will better enable the Company to progress our core NXP002 and NXP004 programmes and respond to requests for additional data as we continue partnering interactions for these programmes.”

Nuformix Plc is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Nuformix advances NXP002 programme with £168,750 Placing

Nuformix plc (LON:NFX) raises £168,750 for fibrosis drug development through a new share placing, advancing its NXP002 programme and corporate goals.

Nuformix plc Annual Results for the period ended 30 September 2024

Nuformix plc (LON:NFX) targets unmet needs in fibrosis and oncology via drug repurposing, focusing on partnering its NXP002 lead program for IPF and PPF.

Nuformix submits NXP002 Orphan Drug Designation Application to EMA

Nuformix plc (LON:NFX) advances NXP002 for Idiopathic Pulmonary Fibrosis, applying for Orphan Drug Designation with European Medicines Agency.

Nuformix submits NXP002 Orphan Drug Designation draft application

Nuformix plc targets fibrosis and oncology needs through drug repurposing, submitting a draft for EMA Orphan Drug Designation for NXP002 in IPF.

Nuformix Executive Director discusses patent updates, interim results and future plans (LON:NFX)

Nuformix plc (LON:NFX) Executive Director Dr. Dan Gooding reveals insights on new patents for NXP002 & NXP004, interim results, and future plans in an exclusive interview.

Nuformix Secures Key Patents and Outlines Future Plans for NXP002 and NXP004 (VIDEO)

Nuformix Plc provides a patent update for its NXP002 and NXP004 programs in fibrosis and oncology. Learn more in this interview with Executive Director Dr. Dan Gooding.

Search

Search